Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. BioDuro, LLC
EIR
•BioDuro, LLC•September 6, 2019

BioDuro, LLC – FDA EIR, Sep 6, 2019

Record Details

An FDA inspection of Anchen Pharmaceuticals, Inc. in Irvine, CA, was conducted from September 3-6, 2019, as a surveillance and Drug Quality Reporting System (DQRS) inspection, following cGMP regulations. The inspection identified several significant issues, leading to a four-item Form FDA-483. Main violations included the company's inadequate testing procedures for incoming active pharmaceutical ingredients (APIs), specifically Bupropion HCl USP, which repeatedly led to particulate contamination and product rejections. Additionally, the firm had not established a hold time for purified water used in manufacturing. Laboratory records were found deficient, lacking complete documentation of all calculations, such as those for system suitability standards in dissolution analysis. Anchen also failed to submit a required NDA-Field Alert Report within three working days after discovering black particles in a distributed batch of Bupropion HCl ER tablets, a failure attributed to an insufficient re-evaluation of the issue. Finally, the Quality Assurance unit did not consistently follow its procedures for closing deviation reports, leaving critical investigations open and sources of contamination undetermined. Three verbal observations also highlighted the absence of defined limits for "technically unavoidable particles," calibration program gaps, and insufficient electronic audit trail review documentation. Management committed to providing a written response with corrective actions within 15 business days to address these regulatory deficiencies.

Company
BioDuro, LLC
Inspection date
September 6, 2019
Product type
drugs
Office
Los Angeles District Office
Person
  • Linda F. Murphy (SVP Consulting & Operations)
View Company Profile

ID · b732ada4-12cd-424d-8eaa-778f097ab05e

Violation Codes4
21 CFR 314.81(b)(1)(ii)21 CFR 211.160(b)21 CFR 211.194(a)(5)21 CFR 211.22(d)

Full citation text and observation details available on the Dashboard.

Other documents for BioDuro, LLC
  • 483 - 2024-02-23February 23, 2024
  • 483 - 2019-09-06September 6, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore BioDuro, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.